Current role of carbamazepine and oxcarbazepine in the management of epilepsy

被引:108
作者
Beydoun, Ahmad [1 ]
DuPont, Sophie [2 ,3 ,4 ]
Zhou, Dong [5 ]
Matta, Maha [6 ]
Nagire, Venkatramana [7 ]
Lagae, Lieven [8 ,9 ]
机构
[1] Amer Univ Beirut, Dept Neurol, Med Ctr, Beirut, Lebanon
[2] Hop La Pitie Salpetriere, AP HP, Epilepsy Unit,CNRS,UMRS 975,INSERM, Ctr Rech,Inst Cerveau & Moelle Epiniere ICM,UMPC, Paris, France
[3] Hop La Pitie Salpetriere, AP HP, Rehabil Unit,CNRS,UMRS 975,INSERM, Ctr Rech,Inst Cerveau & Moelle Epiniere ICM,UMPC, Paris, France
[4] Univ Paris Sorbonne, Paris, France
[5] Sichuan Univ, West China Hosp, Dept Neurol, Chengdu, Sichuan, Peoples R China
[6] Novartis Pharma Serv, Dubai, U Arab Emirates
[7] Novartis Pharmaceut, Mumbai, Maharashtra, India
[8] Katholieke Univ Leuven, Dept Dev & Regenerat, Leuven, Belgium
[9] Univ Hosp Leuven, Dept Pediat, Leuven, Belgium
来源
SEIZURE-EUROPEAN JOURNAL OF EPILEPSY | 2020年 / 83卷
关键词
Carbamazepine; Oxcarbazepine; Epilepsy guidelines; Real-world effectiveness; Focal onset seizures; Therapeutic strategy; CONTROLLED-RELEASE CARBAMAZEPINE; NEWLY-DIAGNOSED EPILEPSY; ANTIEPILEPTIC DRUG EXPOSURE; TONIC-CLONIC SEIZURES; NEW-ONSET EPILEPSY; DOUBLE-BLIND; PEDIATRIC-PATIENTS; TREATMENT GAP; INDUCED HYPONATREMIA; MALFORMATION RISKS;
D O I
10.1016/j.seizure.2020.10.018
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Epilepsy is one of the most common neurological disorders, affecting approximately 50 million people worldwide. Despite a dramatic increase in treatment options over the past 30 years, it still ranks fourth in the world's disease burden. There are now close to 30 antiepileptic drugs (AEDs), with more than two thirds introduced to the market after carbamazepine (CBZ) and one third after its derivative, oxcarbazepine (OXC). Following the introduction of these newer AEDs, the role of CBZ and OXC in the therapeutic armamentarium for seizure control and effective epilepsy management needs to be reviewed. The main guidelines list both CBZ and OXC as first-line options or second-line alternatives for the treatment of focal-onset epilepsy and primary generalized tonic-clonic seizures. While evidence suggests that overall AEDs have similar efficacy, some newer AEDs may be better tolerated than CBZ. In line with this, there have been changes in treatment patterns, with many variations across different countries. However, CBZ remains among the two or three most prescribed drugs for focal epilepsy in many countries, and is widely used across Europe, Africa, South America, and Asia, where it represents a good compromise between cost, availability, and effectiveness. OXC is among the first-choice options for the initial treatment of focal-onset seizures in several countries, including the US and China, where the oral suspension is commonly prescribed. This review provides guidance on the optimal use of these two drugs in clinical practice, including in children, the elderly, and in pregnancy.
引用
收藏
页码:251 / 263
页数:13
相关论文
共 50 条
[31]   The examination of antinociceptive and toxic effects of oxcarbazepine and carbamazepine in mice [J].
Stepanovic-Petrovic, R. M. ;
Tomic, M. A. ;
Vuckovic, S. M. ;
Ugresic, N. ;
Prostran, M. S. ;
Boskovic, B. .
ACTA PHARMACOLOGICA SINICA, 2006, 27 :86-87
[32]   The regulation of serum sodium after replacing carbamazepine with oxcarbazepine [J].
Isojärvi, JIT ;
Huuskonen, UEJ ;
Pakarinen, AJ ;
Vuolteenaho, S ;
Myllylä, VV .
EPILEPSIA, 2001, 42 (06) :741-745
[33]   Opioidergic mechanisms are not involved in the antihyperalgesic effects of carbamazepine and oxcarbazepine [J].
Stepanovic-Petrovic, R. M. ;
Tomic, M. A. ;
Vuckovic, S. M. ;
Ugresic, N. D. ;
Prostran, M. S. ;
Boskovic, B. .
METHODS AND FINDINGS IN EXPERIMENTAL AND CLINICAL PHARMACOLOGY, 2007, 29 (03) :191-194
[34]   Oxcarbazepine versus phenytoin monotherapy for epilepsy [J].
Nolan, Sarah J. ;
Muller, Martie ;
Smith, Catrin Tudur ;
Marson, Anthony G. .
COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2013, (05)
[35]   Current Perspectives On The Role Of The Ketogenic Diet In Epilepsy Management [J].
Goswami, Jyotindra Narayan ;
Sharma, Suvasini .
NEUROPSYCHIATRIC DISEASE AND TREATMENT, 2019, 15 :3273-3285
[36]   Risk Factors of Oxcarbazepine-Induced Hyponatremia in Patients With Epilepsy [J].
Lin, Chih-Hsiang ;
Lu, Cheng-Hsien ;
Wang, Fu-Jung ;
Tsai, Meng-Han ;
Chang, Wen-Neng ;
Tsai, Nai-Wen ;
Lai, Shung-Lon ;
Tseng, Yu-Lung ;
Chuang, Yao-Chung .
CLINICAL NEUROPHARMACOLOGY, 2010, 33 (06) :293-296
[37]   Randomized trial of betahistine mesilate tablets as augmentation for oxcarbazepine and carbamazepine in treating vestibular paroxysmia [J].
Xue, Hui ;
Xiang, Wenping ;
Yu, Yichuan ;
Liu, Guorong ;
Chong, Yi ;
Zhou, Jiying .
DRUG DESIGN DEVELOPMENT AND THERAPY, 2018, 12 :837-843
[38]   Safety, tolerability and effectiveness of transition to eslicarbazepine acetate from carbamazepine or oxcarbazepine in clinical practice [J].
Rocamora, Rodrigo ;
Peltola, Jukka ;
Assenza, Giovanni ;
McMurray, Rob ;
Villanueva, Vicente .
SEIZURE-EUROPEAN JOURNAL OF EPILEPSY, 2020, 75 :121-128
[39]   The longitudinal effect of oxcarbazepine on thyroid function in children and adolescents with epilepsy [J].
Park, Hyunju ;
Heo, Jung ;
Kim, Min-Ji ;
Lee, Jee-Hun ;
Kim, Min-Sun ;
Jin, Dong-Kyu ;
Kim, Tae Hyuk ;
Chung, Jae Hoon ;
Cho, Sung Yoon ;
Kim, Sun Wook .
EPILEPSIA, 2022, 63 (12) :3148-3155
[40]   Carbamazepine and oxcarbazepine in adult patients with Dravet syndrome: Friend or foe? [J].
Snoeijen-Schouwenaars, F. M. ;
Veendrick, M. J. B. M. ;
van Mierlo, P. ;
van Erp, G. ;
de Louw, A. J. A. ;
Kleine, B. U. ;
Schelhaas, H. J. ;
Tan, I. Y. .
SEIZURE-EUROPEAN JOURNAL OF EPILEPSY, 2015, 29 :114-118